Phase 1 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 70 years old
• People who have been diagnosed with Acute Myeloid Leukemia (AML) — a type of blood cancer — in a hospital setting
• People whose AML has stopped responding to multiple standard first-line treatments, or whose disease has come back after initial treatment did not work, and who are expected to live for more than three months
• People whose AML cells test positive for a protein called CD123, with that protein present on at least 20% of the cancer cells (measured by a lab test called flow cytometry)
• People who score between 0 and 2 on the ECOG performance scale, or above 80 on the Karnofsky scale — both are ways doctors measure how well a person is able to carry out daily activities (confirm with trial site)
• People who have a suitable healthy donor available and who agree to allow that donor to give a blood sample

Who may not be able to join:

• People diagnosed with a specific subtype of AML called Acute Promyelocytic Leukemia (APL)
• People whose AML cells test negative for CD123, or where CD123 is present on fewer than 20% of cancer cells
• People who are still experiencing side effects of grade 2 or higher (moderate or worse) from previous treatments, affecting parts of the body other than blood
• People who need immunosuppressant medicines to manage a serious complication called Graft-Versus-Host Disease (a condition where donated cells attack the body) rated grade II–IV
• People who have received steroid medicines throughout the body (not creams or inhalers) in the 7 days before the first study treatment, unless it was a short-term preventive dose
• People who have had serious heart or brain-related medical events in the 6 months before the first dose, have significantly reduced heart function, uncontrolled dangerous heart rhythm problems, or other heart or brain conditions the trial doctor considers unsuitable
• Women who are pregnant or breastfeeding, as the safety of this treatment for unborn babies is not yet known; a pregnancy test must be negative within 48 hours before treatment
• People with active Hepatitis B, Hepatitis C, HIV/AIDS, a high level of a virus called CMV in the blood (500 copies/mL or more), or any other active infection that is not under control
• People who are known to be allergic to immunotherapy treatments or related medicines
• People with certain neurological (brain or nerve) conditions, such as neurodegenerative diseases, brain tumours or infections, multiple sclerosis, epilepsy, or severe nerve damage

Important: Always verify eligibility with the trial site directly before applying.